For instance, increasing evidence suggests that elevated levels of matrix metalloproteinases (MMPs), including MMP2, MMP9, and MMP14, in the brains of AD patients contribute to pathophysiological processes such as neuroinflammation.[37] Expanding the capacity of this assay to include these factors could lead to a more thorough evaluation of AD and offer better insights for personalized care and treatment strategies. This evidence concerns the gene MMP9 and Alzheimer disease.